Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ress in advancing programs within its late-stage development pipeline. These programs have significant potential to drive the company's growth beyond 2011.

Mozobil(TM) (plerixafor) for stem-cell transplantation

-- Genzyme plans to file mid year for U.S. and European approval for

Mozobil's use in treating patients with multiple myeloma and patients

with lymphoma. The company expects to launch the product in the United

States early next year upon approval and to rapidly expand the

product's availability around the world. The company anticipates peak

annual sales of the product in the transplant setting of $400 million.

Mozobil is an innovative product intended to enhance the mobilization

of stem cells for transplantation in patients with lymphoma and

multiple myeloma. In two pivotal clinical studies, Mozobil showed the

ability to quickly and predictably prepare cancer patients for a

transplant to treat their disease. Genzyme is also exploring

additional indications for Mozobil, including its potential use in

chemosensitization procedures.

Clolar for adult AML

-- Clolar is approved in the United States and Europe for the treatment of

acute lymphoblastic leukemia in relapsed and refractory pediatric

patients. Genzyme is developing the product for use globally as a

first-line therapy for the treatment of adult acute myeloid leukemia

(AML) and myelodysplastic syndromes, significantly larger indications

that the company estimates will drive peak annual sales of the product

to approximately $600 million. The company intends to submit a

supplemental new drug application in the United States later this year

to include an adult AML indication. This application will be based on

results from the CLASSIC II clinical trial involving older adult AML

<
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Bioptigen announced today the availability ... the optical device metrology and pre-clinical ophthalmic research markets. ... for Contact Lens Metrology is designed for non-destructive, non-contact, ... lens, IOL structures, and donor tissues. The ... immersed in a hydration bath (saline), automated segmentation of ...
(Date:9/15/2014)... -- iVinci Health LLC, the company behind the healthcare industry,s ... as VisitPay®, has successfully closed $5 million in new ... new extension to VisitPay® – an online Payment and ... for patients to manage their medical bills and set-up ... families. The new round of funding, which ...
(Date:9/15/2014)... AUSTIN, Texas , Sept. 15, 2014 The ... changes in climate, says a new article published by the ... Ahmed , PhD, on climate change and its effects on ... part of an extensive study conducted by Dr. Ahmed in ... China and has implications for the future ...
(Date:9/15/2014)... 15. September 2014 Die zweite jährliche ... vom 12. bis 18. Oktober stattfinden. Die IPAW ... Therapeutics Association (PPTA) und ihrer Mitgliedsunternehmen ... Das globale Bewusstsein für die Gewinnung von Quellplasma ... beim Retten und Verbessern von Leben zu würdigen ...
Breaking Biology Technology:Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3
... for Nanotechnology (LCN) have discovered electronic stripes, called ,charge ... that make up a graphitic superconductor. This is the ... and the finding is likely to have profound implications ... scientists believe will play a key role in the ...
... Inc. (NYSE: WPI ) today announced that ... the United States Food and Drug Administration for its ... and 0.02 mg ethinyl estradiol), a generic version of ... in patent litigation with Bayer concerning this product.  ...
... HAYWARD, Calif., Nov. 29, 2011 Metabolex, Inc., ... development of proprietary new medicines for the treatment ... has been recognized in Windhover,s "Top 10 most ... a potential best-in-class treatment for gout that not ...
Cached Biology Technology:Graphene earns its stripes 2Watson's Generic Yaz(R) Receives FDA Approval 2Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch 2Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch 3
(Date:9/15/2014)... produced naturally across all kingdoms of life and constitute ... range of biological activities. The presence of halogen substituents ... their molecular properties. , One of the ... the late-stage, site-specific incorporation of a halogen atom into ... bond (one of the most inert chemical bonds known ...
(Date:9/15/2014)... new strategic vision document, released today by the ... the long-term goals, objectives, and strategies for the ... over the next five years (2015-2020). In ... activities, to be funded in 2015, will include ... fellowships. , The $500 million, 30-year program ...
(Date:9/15/2014)... that affect hearing and cognitive function may play roles ... and perceive rhythm, pitch, timbre, tone durations, and formal ... BioEssays article explain that extremes in musical aptitude ... the majority of individuals having moderate aptitude. , "This ... to several underlying genes, and it is influenced to ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... propose ever-larger conservation areas in the tropics, ones that ... banding together with their community leaders who ultimately determine ... parts of the world., "When people sacrifice to conserve, ... Christie, University of Washington associate professor of marine affairs ...
... Alexandria, Va. The American Association for Dental ... 2010 AADR Neal W. Chilton Fellowship in Clinical Research ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... and associate director of the Delta Dental of Kentucky ...
... the first-ever data to show that the enzyme calcineurin is ... and that loss of the protein leads to heart problems ... in the Journal of Biological Chemistry as the ... research was led by scientists at Cincinnati Children,s Hospital Medical ...
Cached Biology News:Local social dynamics key to success of tropical marine conservation areas 2Scientists identify critical enzyme in healthy heart function 2